What it sells
Detector of cancer biomarkers.
Business model breakdown
Buyer: who owns the budget?
UnverifiedLab heads / core-facility managers purchasing benchtop instruments and consumables.
Trigger: what makes them buy now?
Need to identify, count and sort nano-objects that conventional flow cytometers cannot, e.g. for EV biomarker development.
Workflow: what inputs become what output?
Load a 50 microliter sample, count in about 2 minutes (NanoCounter) or sort subpopulations with dual-color fluorescence (NanoSorter), harvest concentrated output for omics or functional assays; export .csv/.fcs with automated reporting.
Economics: what it saves and how it charges
Instrument sales (NanoCounter, NanoSorter) plus recurring consumables (chips, packs, oil) and in-house sample services.
Distribution: how it reaches customers
Direct quote-based sales ("Request a quote"), conferences and publications.
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| 2026-07-21 | — | 2,4 millions d'euros | — | news.google.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.